Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.54 |
| ▸ | LPL | P06858 | 10/20 | 0.54 |
| ▸ | F11 | P03951 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25985599 | 0.84 | LIPG (0.57) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL25985572 | 0.84 | LIPG (0.57) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL870004 | 0.84 | LIPG (0.61) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL25981613 | 0.83 | LIPG (0.56) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL25981605 | 0.83 | LIPG (0.59) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1129175 | 0.83 | LIPG (0.59) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL13507405 | 0.81 | LPL (0.50) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL17457 | 0.81 | NR1H2 (0.50) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL24028674 | 0.80 | LIPG (0.65) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL19305515 | 0.80 | LIPG (0.65) | LIPGLPLF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4186906-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257383-A1 | COMPOUND SERVING AS BTK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE1, WEE2 | LIPG 3280/4885LPL 3691/4885F11 347/4885 |
| US-20230364079-A1 | COMPOUND AS BRAIN-PERMEABLE BTK OR HER2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | BTK, WEE2, WEE1 | LIPG 1966/4885LPL 3112/4885F11 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.